ArticleBMC ophthalmology2025
Decreased miR-455-3p promotes diabetic retinopathy progression via modulating retinal endothelial proliferation and apoptosis.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Noncoding RNAs as novel diagnostic biomarkers for diabetic retinopathy: A systematic review and meta-analysis.Journal of diabetes investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic retinopathy (DR) is one of the common ocular complications of diabetes. Recent studies have also found that miR-455-3p is dysregulated in DR. However, its underlying mechanisms warrant further investigation.
objectiveThis study focused on the clinical value of miR-455-3p and its regulatory mechanisms in DR. MATERIALS AND
methodsThis study recruited 130 patients with DR and 105 healthy individuals. HRMECs treated with high glucose were used to simulate DR conditions. The expression of miR-455-3p and Integrin beta 1(ITGB1) were assessed by qRT-PCR while the target relationship between them was validated via Dual-luciferase reporter assay. ROC curve was utilized for the diagnostic performance. CCK-8 and flow cytometry were employed for proliferation and apoptosis measurement while ELISA was used for inflammation.
resultsSerum miR-455-3p was found to be distinctly downregulated in patients with DR. The expression of serum miR-455-3p was negatively associated with HbA1c levels in patients with DR. The miR-455-3p also exhibited strong diagnostic potential for distinguishing patients with DR from healthy individuals. In high glucose-induced HRMECs, miR-455-3p was significantly downregulated. miR-455-3p can target and negatively regulate ITGB1, thereby inhibiting the proliferation and inflammation of HRMECs induced by high glucose and promoting cell apoptosis.
conclusionDecreased miR-455-3p promotes diabetic retinopathy progression via negative regulation on ITGB1. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.